Bundibugyo Ebola Virus Detection Made Easier with New Battery-Powered Device
Text
A new battery-powered diagnostic device developed by Aptamer has been shown to detect the Bundibugyo Ebola virus in 30 minutes, according to a report from News-Medical. The device, which uses nucleic acid detection technology, represents a significant advancement in rapid infectious disease diagnostics, particularly for regions with limited laboratory infrastructure.
The technology relies on aptamers—synthetic molecules designed to bind specifically to viral genetic material—to identify the presence of the Bundibugyo strain of Ebola virus. Unlike traditional polymerase chain reaction (PCR) tests, which require specialized equipment and hours to process, the new device operates independently and delivers results within half an hour. This capability could streamline outbreak response efforts, enabling earlier isolation of infected individuals and reducing transmission risks.
According to the report, the device was validated through trials conducted in collaboration with public health researchers in sub-Saharan Africa. Field tests demonstrated a 98% accuracy rate in detecting the virus, with no false positives reported. The device’s portability and low power requirements make it suitable for use in remote areas, where access to centralized laboratories is limited.
The Bundibugyo Ebola virus, first identified in 2007 in the Democratic Republic of the Congo, is one of four known Ebola virus species. While less lethal than the Zaire strain, it has caused smaller outbreaks with high fatality rates. Rapid diagnostics are critical for containing outbreaks, as early intervention can prevent widespread transmission.
Aptamer’s research team emphasized that the device is not limited to Ebola detection. The same platform could be adapted to identify other pathogens, including malaria and tuberculosis, by modifying the aptamer sequences. “This technology offers a versatile framework for point-of-care diagnostics,” said a spokesperson for the company, who noted that regulatory approvals are pending in several African nations.
Public health officials have welcomed the development as a potential tool for strengthening surveillance in endemic regions. Dr. Amina Jalloh, an epidemiologist at the World Health Organization, stated that “devices like this could transform how we respond to emerging infectious diseases, particularly in resource-limited settings.”
However, challenges remain. The device’s current cost and manufacturing scalability are under review, with Aptamer aiming to reduce production expenses to ensure affordability. Additionally, while the prototype has shown promise in controlled trials, real-world effectiveness may vary depending on environmental conditions and user training.
The development aligns with global efforts to improve diagnostic access, following the lessons of the COVID-19 pandemic. Rapid, portable tests have become a priority for health systems worldwide, and this device could serve as a model for future innovations.
Text
Subheading
How the Device Works
The device functions by extracting and amplifying viral RNA from a blood or saliva sample. Once the genetic material is isolated, aptamers specific to the Bundibugyo Ebola virus bind to target sequences, triggering a color change visible to the naked eye. This visual indicator eliminates the need for complex readout equipment, simplifying use in low-resource settings.
Text
Subheading
Implications for Global Health
Rapid diagnostics are crucial for controlling outbreaks, as they allow health workers to isolate cases and trace contacts more efficiently. In regions where Ebola has historically emerged, such as the Democratic Republic of the Congo and Uganda, this tool could reduce response times and save lives.
Public health experts also highlighted the device’s potential to address diagnostic gaps for other diseases. By repurposing the aptamer system, researchers could develop tests for mpox, influenza, or even emerging variants of SARS-CoV-2.
Text
Subheading
Next Steps and Challenges
Aptamer plans to conduct larger-scale trials in 2027, with the goal of securing approval from the World Health Organization and national health authorities. The company has also partnered with local governments to explore distribution strategies, prioritizing areas with recent Ebola outbreaks.
Despite its promise, the device faces hurdles. Manufacturing at scale requires investment, and ensuring consistent performance across diverse settings will be critical. Additionally, training programs for healthcare workers will need to be developed to maximize the tool’s impact.
Text
Subheading
A Broader Shift in Diagnostic Technology
The device reflects a growing trend toward decentralized, user-friendly diagnostic tools. Similar innovations, such as CRISPR-based tests for SARS-CoV-2, have already demonstrated the feasibility of rapid, portable testing. Analysts suggest that aptamer technology could further reduce reliance on centralized labs, particularly in low-income countries.
Health officials noted that while the device is not a standalone solution, it complements existing strategies for disease control. “It’s another layer in the toolbox,” said Dr. Jalloh. “But it’s a powerful one.”